Table 3.

A summary of existing clinical trials on the use of LDN in the treatment of cancer.

NCT Number	Status	Cancer	Treatment	Phase	Participants	Results/Comments	References
NCT05968690	Study Start (Actual)	Advanced Melanoma	Propranolol 30 mg + Naltrexone 4.5 mg	I	12	Study Completion (Estimated) 30 September 2025	[109]
NCT01650350	Enrollment (Actual)	Melanoma, Prostate Cancer, Renal Cancer	LDN, 5 mg/day − (1 cycle = 28 days)	II	7	Results N/A	[108]
NCT01303835	Enrollment (Actual)	Glioma	LDN, 4.5 mg	II	110	QOL and fatigue changes between baseline and post-concurrent chemotherapy and radiation therapy were not significantly different between patients receiving LDN or placebo.	[107]